Galantamine Pill

Phase 1Small molecule

Galantamine Pill is one of 2 small molecule programs targeting Postural Tachycardia Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postural Tachycardia SyndromeActive, not recruiting

Postural Tachycardia SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Postural Tachycardia Syndrome

#DrugCompanyPhaseTrials

Moxonidine

SSolvay Pharmaceuticals

Phase 1

—2

Galantamine Pill

VVanderbilt University Medical Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Postural Tachycardia Syndrome

NCT03124355

Clinical

Trials by Indication[1]

Postural Tachycardia Syndrome1 trial

Vagal Stimulation in POTS - The Autonomic Inflammatory Reflex (Pilot 3)

Active, not recruiting·VVanderbilt University Medical Center·Phase 1·NCT03124355·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Galantamine Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Galantamine Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Galantamine Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVanderbilt University Medical Center

Galantamine Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Postural Tachycardia Syndrome1 trial

References

Drug Info

Quick Facts

Related News